Clinical Care Considerations for COVID-19 Vaccination

Janssen COVID-19 Vaccine (Johnson & Johnson): Effective April 23, 2021, CDC and FDA recommend that use of the Janssen COVID-19 Vaccine resume in the United States. However, women younger than 50 years old especially should be made aware of a rare risk of blood clots with low platelets following vaccination and the availability of other COVID-19 vaccines where this risk has not been observed. Read the CDC/FDA statement.

Learn more:

The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech, Moderna, ​and Janssen/Johnson & Johnson COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States. You can find these recommendations as well as clinical considerations for managing adverse events below.

Use of COVID-19 Vaccines

Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States.

Vaccinating Special Populations
Page last reviewed: August 23, 2021